Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Gordon

Showing results (861-870 of 1,032) with videos related to

Pageof 104
Sort By:
Nature|September 23, 2008
Innate immunity and intestinal microbiota in the development of Type 1 diabetesLi Wen, Ruth E Ley, Pavel Yu Volchkov, et al.
British Journal of Haematology|April 27, 2007
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysisAndrew M Evens, Jeffrey Cilley, Taylor Ortiz, et al.
Public Health Action|March 3, 2025
Comparative analysis of the impact of portable digital X-ray on TB screening in hard-to-reach areas in NigeriaS Useni, B Odume, M Tukur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphomaT E Witzig, C A White, G A Wiseman, et al.
Cancer Discovery|August 30, 2018
<i>In Situ</i> Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent LymphomaMatthew J Frank, Patrick M Reagan, Nancy L Bartlett, et al.
Cancer|December 15, 1980
Small-cell carcinoma of the lung: a five-year experience with combined modality therapyP C Hoffman, H M Golomb, J D Bitran, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2006
The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: evolution during disease progressionJung D Oh, Helene Kling-Bäckhed, Marios Giannakis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphomaAnas Younes, Stella Kim, Jorge Romaguera, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
Integrative genomic reconstruction of carbohydrate utilization networks in bifidobacteria: global trends, local variability, and dietary adaptationAleksandr A Arzamasov, Dmitry A Rodionov, Matthew C Hibberd, et al.
Leukemia & Lymphoma|August 2, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomasWilliam B Pearse, Adam M Petrich, Leo I Gordon, et al.
Pageof 104

Showing results (861-870 of 1,032) with videos related to

Sort By:
Pageof 104
Nature|September 23, 2008
Innate immunity and intestinal microbiota in the development of Type 1 diabetesLi Wen, Ruth E Ley, Pavel Yu Volchkov, et al.
British Journal of Haematology|April 27, 2007
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysisAndrew M Evens, Jeffrey Cilley, Taylor Ortiz, et al.
Public Health Action|March 3, 2025
Comparative analysis of the impact of portable digital X-ray on TB screening in hard-to-reach areas in NigeriaS Useni, B Odume, M Tukur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphomaT E Witzig, C A White, G A Wiseman, et al.
Cancer Discovery|August 30, 2018
<i>In Situ</i> Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent LymphomaMatthew J Frank, Patrick M Reagan, Nancy L Bartlett, et al.
Cancer|December 15, 1980
Small-cell carcinoma of the lung: a five-year experience with combined modality therapyP C Hoffman, H M Golomb, J D Bitran, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2006
The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: evolution during disease progressionJung D Oh, Helene Kling-Bäckhed, Marios Giannakis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphomaAnas Younes, Stella Kim, Jorge Romaguera, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
Integrative genomic reconstruction of carbohydrate utilization networks in bifidobacteria: global trends, local variability, and dietary adaptationAleksandr A Arzamasov, Dmitry A Rodionov, Matthew C Hibberd, et al.
Leukemia & Lymphoma|August 2, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomasWilliam B Pearse, Adam M Petrich, Leo I Gordon, et al.
Pageof 104